CAR-T therapy for autoimmune diseases is an innovative treatment originally developed for certain blood cancers. Today, it is being tested in clinical trials as a potential breakthrough for rheumatic diseases—autoimmune conditions in which the immune system attacks healthy tissue.
A new CAR-T clinical trial in Israel launched in June 2025, offering access to this cutting-edge therapy for patients with severe and treatment-resistant rheumatic conditions. Eligibility is limited to patients who have failed at least 2–3 standard treatments.
Autoimmune diseases currently included in the program are:
- Lupus (SLE) – CAR-T for lupus is showing promising early results.
- Rheumatoid arthritis
- Systemic Sclerosis (SSC or Scleroderma)
- Dermatomyositis
- Vasculitis
- Sjögren’s syndrome
To participate, patients must stay in Israel for about 8–10 weeks. This ensures proper medical supervision during the CAR-T cell infusion and recovery period.
This program marks a promising step forward in CAR-T therapy for rheumatic diseases, offering new hope for those who haven’t found relief with existing treatments.
To check your eligibility, please email us:
- A summary of your previous treatments, from diagnosis until today
- Recent blood test results that include autoimmune markers commonly assessed in rheumatology. These include: RF, ACPA, ANA, ANCA, SCL-70, Anti-Centromere, Anti-RNA Polymerase III, Anticardiolipin, and Anti-Beta-2 Glycoprotein I
